前收市價 | 5.58 |
開市 | 5.56 |
買盤 | 5.28 x 100 |
賣出價 | 5.34 x 100 |
今日波幅 | 5.24 - 5.56 |
52 週波幅 | 2.13 - 7.73 |
成交量 | |
平均成交量 | 626,786 |
市值 | 255.498M |
Beta 值 (5 年,每月) | 1.31 |
市盈率 (最近 12 個月) | 11.78 |
每股盈利 (最近 12 個月) | 0.45 |
業績公佈日 | 2024年5月02日 - 2024年5月06日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 4.33 |
Puma Biotechnology (PBYI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The FDA removes the clinical hold on Iovance's (IOVA) mid-stage study on LN-145 in certain NSCLC patients after reviewing the company's proposal for additional safety measures and monitoring.
The approval is based on data from a late-stage study wherein treatment with J&J's (JNJ) Rybrevant plus chemotherapy reduced the disease-progression risk or death by 61% in certain NSCLC patients.